Eupraxia Pharmaceuticals (EPRX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- —
- Estimate
- -$0.23
- Surprise
- —
- Score today
- 5.2/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Eupraxia Pharmaceuticals Q2 EPS $(0.23), Inline — benzinga, 2026-08-11
Where TrendMatrix's rating stands now
TrendMatrix currently rates EPRX Sell at 5.2/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-03.
What argues against it
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $6.73
- Price target
- $14.22
- Stop
- $6.26
- Upside to target
- +111.3%
- Reward-to-risk
- 7.7:1
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
EPRX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $443.6M
- P/E (fwd)
- -6.6
- 52-week range
- $5.04–$9.32
- Off 52-week high
- 27.8%
- RSI (14)
- 57
- Volume vs avg
- 0.88×
- Score today
- 5.2/10